.png)
Inspira Technologies
Respiratory/extracorporeal life support (ART100 CPB/ECMO; ART500 awake oxygenation) + HYLA non-invasive blood sensor
Latest event found: 30 May 2026 · 5 months ago
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
Inspira is transitioning from an R&D-led respiratory-device company toward commercial deployment of ART100 while diversifying into additive manufacturing and adjacent diagnostic technologies. The strategy shows ambition and multiple growth vectors, but execution remains dependent on regulatory milestones, governmental procurement, and conversion of announced orders into recognized revenue.
Efficiency Ratio
The company demonstrates high innovation output relative to its recorded 11–50-person workforce, but its broadening portfolio and reliance on external procurement and funding processes create execution risk.
Evidence Signals
Inspira announced completion of the acquisition of Nano Dimension's AME platform and stated that control of the acquired assets and operations had transferred immediately.
Inspira entered into an asset purchase agreement and assumed control of Nano Dimension's additive manufacturing electronics and Fabrica-related assets and operations.
Inspira reported that its distribution partner had advanced the $22.5 million and $27 million binding purchase orders to final governmental budgetary authorization, with approximately 91% cleared through earlier review stages.
Inspira announced deployment and initiation of a structured commercial evaluation of the FDA-cleared ART100 at an additional leading academic medical center in New York State.
Inspira reaffirmed $49.5 million in binding purchase orders and said payment activity was structured to begin during the 2026 fiscal cycle, subject to regulatory sequencing and phased deployment milestones.
- About
- Israeli commercial-stage medical-device company (Inspira Technologies Ltd.; Nasdaq: IINN; HQ Ra'anana, Israel; founded 2018; ~11-50 staff) specializing in advanced respiratory/life support and real-time blood monitoring. Its FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the US and used for ECMO (extracorporeal membrane oxygenation) outside the US; it serves as the foundation for the next-generation INSPIRA ART500 (in development), designed to deliver oxygenation while patients remain awake and spontaneously breathing — an alternative to conventional mechanical ventilation. Inspira is also developing HYLA, a proprietary non-invasive blood-sensor platform for continuous monitoring. Defense relevance: acute respiratory / extracorporeal life support is relevant to severe-casualty resuscitation and critical-care transport (dual-use), with no defense-specific contract confirmed.
- Tags
- #respiratory #ecmo #cardiopulmonarybypass #lifesupport #criticalcare #ventilation #art100 #fda #nasdaq #dualuse